Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Lexeo Therapeutics, Inc. Common Stock

Company price
3.115 USD -0.12 ( 3.56%)
Last update at 2026-11-17T17:46:00Z
VOLUME
1877090
Market Cap
338.85M

Momentum Score

…

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.08
Low
3.40
High
52 Week Price Range
3.99
Low
10.99
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.23
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-66.64M
Debt / Equity
0.03
ROE
-46.76%
Net Debt
-55.11M
ROCE
-39.60%
Diluted EPS TTM
-0.86

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -99.96M -98.33M -66.39M -59.28M -50.62M
Net income -99.96M -98.33M -66.39M -59.28M -50.62M
Selling general administrative 45.46M 31.68M 15.38M 12.00M 7.17M
Selling and marketing expenses - - 1.84M - -
Gross profit -2.08M -2.00M -1.84M 0.65M 1.66M
Reconciled depreciation 2.08M 2.00M 1.84M 1.15M 0.01M
Ebit -99.75M -98.20M -66.19M -59.19M -50.62M
Ebitda -97.68M -96.19M -64.35M -58.04M -50.61M
Depreciation and amortization 2.08M 2.00M 1.84M 1.15M 0.01M
Operating income -109.26M -105.77M -68.51M -60.51M -50.64M
Other operating expenses 109.26M 105.77M 68.51M 61.16M 52.29M
Interest expense 0.21M 0.11M 0.20M 0.09M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 6.13M 7.58M 2.87M 1.32M 0.01M
Net interest income 5.92M 7.44M 2.66M 1.23M 0.01M
Income tax expense - - -0.00M 0.09M -0.00M
Total revenue 0.00M 0.00M 0.00M 0.65M 1.66M
Total operating expenses 109.26M 105.77M 68.51M 61.16M 52.29M
Cost of revenue 2.08M 2.00M 1.84M - -
Total other income expense net 9.30M 7.43M 2.12M -0.00M -0.00M
Net income from continuing ops -99.96M -98.33M -66.39M -59.28M -50.62M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 268.69M 146.94M 139.81M 97.08M 136.86M
Other current assets 6.62M 4.60M 0.00M 0.37M 0.70M
Total liab 22.02M 30.10M 26.27M 210.03M 192.46M
Total stockholder equity 246.67M 116.84M 113.53M -112.95M -55.60M
Other current liab 9.28M 13.76M 0.17M 8.84M 4.34M
Common stock 0.01M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.00M 0.00M 0.00M 0.00M
Retained earnings -380.13M -280.17M -181.84M -115.45M -56.17M
Cash 63.00M 35.01M 121.47M 77.33M 135.86M
Total current liabilities 16.81M 22.85M 17.24M 14.35M 7.45M
Current deferred revenue - - 10.67M 8.60M 0.05M
Net debt -55.11M -25.09M -109.83M -63.85M -135.86M
Short term debt 2.67M 2.67M 2.60M 2.83M 4.31M
Short long term debt total 7.89M 9.92M 11.64M 13.48M -
Other stockholder equity 626.61M 397.12M 295.37M 2.49M 0.56M
Total current assets 188.39M 126.12M 124.29M 80.05M 136.68M
Long term investments 68.19M 7.01M - - -
Short term investments 118.77M 86.50M - - -
Accounts payable 4.86M 6.42M 3.79M 2.68M 3.06M
Accumulated other comprehensive income 0.19M -0.10M - - -
Non currrent assets other 3.25M 3.25M 3.25M 3.25M 0.00M
Non current assets total 80.30M 20.82M 15.51M 17.03M 0.18M
Capital lease obligations 7.89M 9.92M 11.64M 13.48M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -89.86M -94.08M -0.17M -0.90M -0.19M
Total cashflows from investing activities -90.25M -94.08M -0.17M - -
Net borrowings -0.53M -0.41M 3.58M - -
Total cash from financing activities 216.79M 88.78M 103.79M 0.19M 150.86M
Net income -99.96M -98.33M -66.39M -59.28M -50.62M
Change in cash 27.98M -86.45M 44.13M -55.27M 106.49M
Begin period cash flow 38.27M 124.72M 80.59M 135.86M 29.37M
End period cash flow 66.25M 38.27M 124.72M 80.59M 135.86M
Total cash from operating activities -98.56M -81.15M -59.50M -54.56M -44.18M
Issuance of capital stock 234.02M 88.71M 100.25M 0.02M 151.06M
Depreciation 0.38M 2.00M 1.84M 1.15M 0.01M
Other cashflows from investing activities 0.02M - -0.05M - -
Sale purchase of stock 80.00M -0.02M 0.00M - -
Other cashflows from financing activities 216.79M 0.49M -0.04M 0.35M 150.86M
Capital expenditures 0.40M 0.48M 0.17M 0.90M 0.19M
Change in working capital -9.52M 2.73M 1.48M 1.79M 6.04M
Stock based compensation 12.13M 12.47M 3.04M 1.78M 0.39M
Other non cash items -1.60M -0.02M 0.53M - -
Free cash flow -98.96M -81.63M -59.66M -55.46M -44.37M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LXEO
Lexeo Therapeutics, Inc. Common Stock
-0.12
3.56%
3.12 - 7.60 478.26 1.47 416.34 -6.02
NVO
Novo Nordisk A/S
-0.80
1.91%
40.80 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-2.08
0.39%
535.71 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
9.09
0.95%
961.49 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

345 Park Avenue South, New York, NY, United States, 10010

212 547 9879

63

Name Title Year Born
Mr. R. Nolan Townsend CEO & Director 1981
Dr. Paul B. McCormac Ph.D. Chief Technical Officer 1970
Ms. Jenny R. Robertson Chief Business & Legal Officer 1975
Dr. Ronald G. Crystal M.D. Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board NA
Dr. Eric Adler M.D. Chief Medical Officer & Head of Research 1974
Dr. Jordan Shin M.D., Ph.D. Senior Vice President of Clinical Development & Translational Science, Cardiology NA
Dr. Jordan S. Dubow M.D. Head of CNS Clinical Development 1979
Dr. Sandi See Tai M.D. Chief Development Officer 1971
Mr. Ryan McHenry VP & Corporate Controller NA
Mr. R. Nolan Townsend M.B.A. CEO & Director 1981

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…